Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation is focused on whether Anika has engaged in any unlawful activities that may have led to financial losses for its investors [2]. Stock Price Impact - Following the announcement of the clinical trial results for Hyalofast, Anika's stock price dropped by $3.06 per share, representing a decline of 27.42%, closing at $8.10 per share on July 30, 2025 [6]. - The clinical trial did not meet its pre-specified co-primary endpoints, which was attributed to a higher dropout rate and missed visits during COVID, complicating the statistical analysis [6]. Next Steps for Investors - Investors who purchased Anika shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to financial losses for investors [2]. - The firm is encouraging investors who suffered losses to contact them for further discussion on their legal rights and options [1][3]. Recent Events - On September 29, 2025, MoonLake filed a current report with the SEC, revealing that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a stock price decline of 89.9% on the same day [6].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices [1][2][4] - MoonLake's stock experienced a significant decline of 89.9% on September 29, 2025, following the announcement of disappointing results from its VELA-2 trial, which failed to achieve statistical significance [1][6] Investigation Details - The law firm is reaching out to investors who purchased or acquired MoonLake shares and suffered losses, encouraging them to discuss their legal rights and options [1][3] - The investigation is focused on whether the company misled investors regarding its trial results and overall business practices [1][2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and has a track record in commercial and securities litigation [4]

Core Insights - EHang Holdings Limited is under investigation for potential violations of federal securities laws and unlawful business practices [2] - The company has significantly reduced its 2025 revenue projection from 900 million yuan to 500 million yuan, leading to a decrease in its American Depositary Receipt (ADR) price by $1.34, or 7.53%, closing at $16.45 on August 26, 2025 [3] Company Overview - EHang is a publicly traded company listed on NASDAQ under the ticker EH [2] - The company is facing scrutiny from Bragar Eagel & Squire, P.C., a law firm specializing in stockholder rights [2][5] Financial Impact - The revision of revenue projections has prompted Morgan Stanley to lower its forecasts for EHang [3] - The ADR price drop indicates a negative market reaction to the company's revised financial outlook [3]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Praxis Precision Medicines, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Financial Performance - On August 4, 2025, Praxis reported its second-quarter financial results, including mid-stage study results for its anti-seizure medication vormatrigine, where 36 out of 61 patients experienced treatment-emergent adverse events, and nearly 25% of participants discontinued the study [2]. Stock Market Reaction - Following the announcement of the adverse study results, Praxis's stock price decreased by $3.00 per share, or 5.55%, closing at $51.09 per share on August 4, 2025 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its FDA approval process [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor and its executives made false and misleading statements regarding the efficacy and safety data of deramiocel, particularly in relation to its Phase 2 HOPE-2 trial [4]. - Capricor received a Complete Response Letter (CRL) from the FDA on July 11, 2025, denying the Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [5]. Group 3: Stock Price Impact - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [6].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Boeing regarding possible violations of federal securities laws and unlawful business practices [2] - A recent incident involving a Boeing 787 Dreamliner operated by Air India resulted in a crash shortly after takeoff, leading to a significant drop in Boeing's stock price by $13.68 per share, or 6.39%, closing at $200.32 per share [3] Group 1 - The law firm is encouraging investors who suffered losses in Boeing to contact them for discussions about their legal rights [1][4] - The investigation is focused on whether Boeing has engaged in unlawful practices that may have affected stockholder interests [2] - The firm represents both individual and institutional investors in complex litigation across state and federal courts [5] Group 2 - The crash incident occurred on June 12, 2025, in Ahmedabad, India, raising concerns about Boeing's operational safety [3] - The law firm provides a no-cost consultation for affected investors to explore their options [4] - Contact information for the law firm is provided for investors seeking assistance [7]